A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT07553299 on ClinicalTrials.gov · last registry update 2026-08-04
Closed to new participants; the 120 already enrolled are still being followed. Due to report 30 November 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: To identify the dose of VRB-101 for weight maintenance. Sponsors move these dates routinely; any movement since this site started watching is listed below. ecnoglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P2
- Drug
- ecnoglutide
- Sponsor
- Verdiva Bio Dev Limited
- Sponsor type
- Industry
- Enrollment
- 120
- Started
- 2026-06-12
- Primary completion
- 2026-11-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
To identify the dose of VRB-101 for weight maintenance
Conditions studied
Obesity · Overweight · Weight Maintenance
Every field above is taken directly from the registry record. See all detected changes across the class, or the ecnoglutide page for this molecule’s full trial and approval history.